Advances in the molecular genetics of gliomas-implications for classification and therapy

Nature Reviews Clinical Oncology

Volumn 14, Issue 7, 2017, Pages 434-452

  Reifenberger, Guido ^a,b   Wirsching, Hans Georg ^c,d   Knobbe Thomsen, Christiane B ^a   Weller, Michael ^c  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^d Fred Hutchinson Cancer Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATEZOLIZUMAB; BEVACIZUMAB; CHIMERIC ANTIGEN RECEPTOR; DABRAFENIB; DENDRITIC CELL VACCINE; IPILIMUMAB; ISOCITRATE DEHYDROGENASE 1; ISOCITRATE DEHYDROGENASE 2; LOMUSTINE; LYMPHOCYTE ANTIGEN RECEPTOR; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; NIVOLUMAB; PEMBROLIZUMAB; PLACEBO; PROCARBAZINE; RINDOPEPIMUT; SELUMETINIB; SORAFENIB; T LYMPHOCYTE RECEPTOR; TEMOZOLOMIDE; TUMOR MARKER; VEMURAFENIB; VINCRISTINE;

CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CELL THERAPY; CHROMOSOME 19Q; CHROMOSOME 1P; CHROMOSOME DELETION; CLINICAL STUDY; DNA METHYLATION; DRUG EFFICACY; EPENDYMOMA; EPIGENETICS; GLIOBLASTOMA; GLIOMA; HIGH THROUGHPUT SEQUENCING; HUMAN; HYPOFRACTIONATED RADIOTHERAPY; MOLECULAR DIAGNOSIS; MOLECULAR GENETICS; MULTIPLE CYCLE TREATMENT; NEXT GENERATION SEQUENCING; NONHUMAN; PILOCYTIC ASTROCYTOMA; PLEOMORPHIC XANTHOASTROCYTOMA; PREDICTION; PRIORITY JOURNAL; PROMOTER REGION; REVIEW; SIGNAL TRANSDUCTION; SUBEPENDYMAL GIANT CELL ASTROCYTOMA; TUMOR GROWTH; CENTRAL NERVOUS SYSTEM NEOPLASMS; CLASSIFICATION; GENETICS; MOLECULAR BIOLOGY; PATHOLOGY; PRACTICE GUIDELINE; WORLD HEALTH ORGANIZATION;

CENTRAL NERVOUS SYSTEM NEOPLASMS; GLIOMA; HUMANS; MOLECULAR BIOLOGY; PRACTICE GUIDELINES AS TOPIC; WORLD HEALTH ORGANIZATION;

EID: 85007497602     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2016.204     Document Type: Review

References (206)

1. Rouse, C., Gittleman, H., Ostrom, Q. T., Kruchko, C. & Barnholtz-Sloan, J. S. Years of potential life lost for brain and CNS tumours relative to other cancers in adults in the United States, 2010. Neuro Oncol. 18, 70-77 (2016).
2. Ostrom, Q. T. et al. CBTRUS statistical report: primary brain and central nervous system tumours diagnosed in the United States in 2008-2012. Neuro Oncol. 17, (Suppl. 4) iv1-iv62 (2015).
3. Gilbert, M. R. et al. Dose-dense temozolomide for newly diagnosed glioblastoma: a randomised phase III clinical trial. J. Clin. Oncol. 31, 4085-4091 (2013).
4. Chinot, O. L. et al. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N. Engl. J. Med. 370, 709-722 (2014).
5. Gilbert, M. R. et al. A randomised trial of bevacizumab for newly diagnosed glioblastoma. N. Engl. J. Med. 370, 699-708 (2014).
6. Gramatzki, D. et al. Glioblastoma in the Canton of Zurich, Switzerland revisited: 2005 to 2009. Cancer 122, 2206-2215 (2016).
7. Zong, H., Parada, L. F. & Baker, S. J. Cell of origin for malignant gliomas and its implication in therapeutic development. Cold Spring Harb. Perspect. Biol. 29, 7 (2015).
8. Sturm, D. et al. Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. Cancer Cell 22, 425-437 (2012).
9. Brennan, C. W. et al. The somatic genomic landscape of glioblastoma. Cell 155, 462-477 (2013).
10. Cancer Genome Atlas Research Network. Comprehensive, integrative genomic analysis of diffuse lower-grade gliomas. N. Engl. J. Med. 372, 2481-2498 (2015).
11. Suzuki, H. et al. Mutational landscape and clonal architecture in grade II and III gliomas. Nat. Genet. 47, 458-468 (2015).
12. Ceccarelli, M. et al. Molecular profiling reveals biologically discrete subsets and pathways of progression in diffuse glioma. Cell 164, 550-563 (2016).
13. Schwartzentruber, J. et al. Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature 482, 226-231 (2012).
14. Wu, G. et al. Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas. Nat. Genet. 44, 251-253 (2012).
15. Jones, D. T. et al. Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma. Nat. Genet. 45, 927-932 (2013).
16. Zhang, J. et al. Whole-genome sequencing identifies genetic alterations in pediatric low-grade gliomas. Nat. Genet. 45, 602-612 (2013).
17. Wu, G. et al. The genomic landscape of diffuse intrinsic pontine glioma and pediatric non-brainstem high-grade glioma. Nat. Genet. 46, 444-450 (2014).
18. Buczkowicz, P. et al. Genomic analysis of diffuse intrinsic pontine gliomas identifies three molecular subgroups and recurrent activating ACVR1 mutations. Nat. Genet. 46, 451-456 (2014).
19. Parker, M. et al. C11orf95-RELA fusions drive oncogenic NF-κB signalling in ependymoma. Nature 506, 451-455 (2014).
20. Pajtler, K. W. et al. Molecular classification of ependymal tumours across all CNS compartments, histopathological grades, and age groups. Cancer Cell 27, 728-743 (2015).
21. Korshunov, A. et al. Integrated analysis of pediatric glioblastoma reveals a subset of biologically favorable tumours with associated molecular prognostic markers. Acta Neuropathol. 129, 669-678 (2015).
22. Louis, D. N., Ohgaki, H., Wiestler, O. D. & Cavenee, W. K. (Eds). WHO Classification of Tumours of the Central Nervous System, Revised 4th edn 10-122 (IARC, 2016).
23. Louis, D. N., Ohgaki, H., Wiestler, O. D. & Cavenee, W. K. (Eds). WHO Classification of Tumours of the Central Nervous System, 4th edn 10-80 (IARC, 2007).
24. van den Bent, M. J. Interobserver variation of the histopathological diagnosis in clinical trials on glioma: a clinician's perspective. Acta Neuropathol. 120, 297-304 (2010).
25. Wiestler, B. et al. Integrated DNA methylation and copy-number profiling identify three clinically and biologically relevant groups of anaplastic glioma. Acta Neuropathol. 128, 561-571 (2014).
26. Weller, M. et al. Molecular classification of diffuse cerebral WHO grade II/III gliomas using genome- and transcriptome-wide profiling improves stratification of prognostically distinct patient groups. Acta Neuropathol. 129, 679-693 (2015).
27. Sahm, F. et al. Farewell to oligoastrocytoma: in situ molecular genetics favor classification as either oligodendroglioma or astrocytoma. Acta Neuropathol. 128, 551-559 (2014).
28. Herrlinger, U. et al. Gliomatosis cerebri: no evidence for a separate brain tumour entity. Acta Neuropathol. 131, 309-319 (2016).
29. Louis, D. N. et al. International Society of Neuropathology-Haarlem consensus guidelines for nervous system tumour classification and grading. Brain Pathol. 24, 429-435 (2014).
30. Louis, D. N. et al. The 2016 World Health Organization Classification of Tumours of the Central Nervous System: a summary. Acta Neuropathol. 131, 803-820 (2016).
31. Parsons, D. W. et al. An integrated genomic analysis of human glioblastoma multiforme. Science 321, 1807-1812 (2008).
32. Yan, H. et al. IDH1 and IDH2 mutations in gliomas. N. Engl. J. Med. 360, 765-773 (2009).
33. Balss, J. et al. Analysis of the IDH1 codon 132 mutation in brain tumours. Acta Neuropathol. 116, 597-602 (2008).
34. Weller, M. et al. Glioma. Nat. Rev. Dis. Primers 1, 15017 (2015).
35. Xu, W. et al. Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases. Cancer Cell 19, 17-30 (2011).
36. Noushmehr, H. et al. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell 17, 510-522 (2010).
37. Capper, D. et al. Monoclonal antibody specific for IDH1 R132H mutation. Acta Neuropathol. 118, 599-601 (2009).
38. van den Bent, M. J. et al. Interlaboratory comparison of IDH mutation detection. J. Neurooncol. 112, 173-178 (2013).
39. Reuss, D. E. et al. Adult IDH wild type astrocytomas biologically and clinically resolve into other tumor entities. Acta Neuropathol. 130, 407-417 (2015).
40. Masui, K., Mischel, P. S. & Reifenberger, G. Molecular classification of gliomas. Handb. Clin. Neurol. 134, 97-120 (2016).
41. Sasaki, M. et al. IDH1(R132H) mutation increases murine haematopoietic progenitors and alters epigenetics. Nature 488, 656-659 (2012).
42. Watson, L. A., Goldberg, H. & Birubi, N. G. Emerging roles of ATRX in cancer. Epigenomics 7, 1365-1378 (2015).
43. Bai, H. et al. Integrated genomic characterization of IDH1-mutant glioma malignant progression. Nat. Genet. 48, 59-66 (2016).
44. Mazor, T. et al. DNA methylation and somatic mutations converge on the cell cycle and define similar evolutionary histories in brain tumours. Cancer Cell 28, 307-317 (2015).
45. Griffin, C. A. et al. Identification of der(1;19)(q10;p10) in five oligodendrogliomas suggests mechanism of concurrent 1p and 19q loss. J. Neuropathol. Exp. Neurol. 65, 988-994 (2006).
46. Jenkins, R. B. et al. A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma. Cancer Res. 66, 9852-9856 (2006).
47. Arita, H. et al. Upregulating mutations in the TERT promoter commonly occur in adult malignant gliomas and are strongly associated with total 1p19q loss. Acta Neuropathol. 126, 267-276 (2013).
48. Bettegowda, C. et al. Mutations in CIC and FUBP1 contribute to human oligodendroglioma. Science 333, 1453-1455 (2011).
49. Alentorn, A. et al. Allelic loss of 9p21.3 is a prognostic factor in 1p/19q codeleted anaplastic gliomas. Neurology 85, 1325-1331 (2015).
50. Labreche, K. et al. TCF12 is mutated in anaplastic oligodendroglioma. Nat. Commun. 6, 7207 (2015).
51. Kamoun, A. et al. Integrated multi-omics analysis of oligodendroglial tumours identifies three subgroups of 1p/19q co-deleted gliomas. Nat. Commun. 7, 11263 (2016).
52. Huse, J. T., Diamond, E. L., Wang, L. & Rosenblum, M. K. Mixed glioma with molecular features of composite oligodendroglioma and astrocytoma: a true "oligoastrocytoma"? Acta Neuropathol. 129, 151-153 (2015).
53. Aldape, K., Zadeh, G., Mansouri, S., Reifenberger, G. & von Deimling, A. Glioblastoma: pathology, molecular mechanisms and markers. Acta Neuropathol. 129, 829-848 (2015).
54. Kleinschmidt-De Masters, B. K., Aisner, D. L., Birks, D. K. & Foreman, N. K. Epithelioid GBMs show a high percentage of BRAF V600E mutation. Am. J. Surg. Pathol. 37, 685-698 (2013).
55. Verhaak, R. G. et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterised by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17, 98-110 (2010).
56. Bhat, K. P. et al. Mesenchymal differentiation mediated by NF-κB promotes radiation resistance in glioblastoma. Cancer Cell. 24, 331-346 (2013).
57. Patel, A. P. et al. Single-cell RNA-seq highlights intratumoural heterogeneity in primary glioblastoma. Science 344, 1396-1401 (2014).
58. Sandmann, T. et al. Patients with proneural glioblastoma may derive overall survival benefit from the addition of bevacizumab to first-line radiotherapy and temozolomide: retrospective analysis of the AVAglio trial. J. Clin. Oncol. 33, 2735-2744 (2015).
59. Hawkins, C. et al. BRAF-KIAA1549 fusion predicts better clinical outcome in pediatric low-grade astrocytoma. Clin. Cancer Res. 17, 4790-4798 (2011).
60. ARF/CDKN2B deletion and low TSC1 mRNA expression in pleomorphic xanthoastrocytomas. Oncogene 26, 1088-1097 (2007).
61. Schindler, G. et al. Analysis of BRAF V600E mutation in 1,320 nervous system tumours reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma. Acta Neuropathol. 121, 397-405 (2011).
62. Koelsche, C. et al. BRAF-mutated pleomorphic xanthoastrocytoma is associated with temporal location, reticulin fiber deposition and CD34 expression. Brain Pathol. 24, 221-229 (2014).
63. Alexandrescu, S. et al. Epithelioid glioblastomas and anaplastic epithelioid pleomorphic xanthoastrocytomas - same entity or first cousins? Brain Pathol. 26, 215-223 (2016).
64. Chan, J. A. et al. Pathogenesis of tuberous sclerosis subependymal giant cell astrocytomas: biallelic inactivation of TSC1 or TSC2 leads to mTOR activation. J. Neuropathol. Exp. Neurol. 63, 1236-1242 (2004).
65. Nauen, D. et al. Molecular analysis of pediatric oligodendrogliomas highlights genetic differences with adult counterparts and other pediatric gliomas. Brain Pathol. 26, 206-214 (2016).
66. Qaddoumi, I. et al. Genetic alterations in uncommon low-grade neuroepithelial tumours: BRAF, FGFR1, and MYB mutations occur at high frequency and align with morphology. Acta Neuropathol. 131, 833-845 (2016).
67. Bandopadhayay, P. et al. MYB-QKI rearrangements in angiocentric glioma drive tumourigenicity through a tripartite mechanism. Nat. Genet. 48, 273-282 (2016).
68. Bender, S. et al. Reduced H3K27me3 and DNA hypomethylation are major drivers of gene expression in K27M mutant pediatric high-grade gliomas. Cancer Cell 24, 660-672 (2013).
69. Lewis, P. W. et al. Inhibition of PRC2 activity by a gain-of-function H3 mutation found in pediatric glioblastoma. Science 340, 857-861 (2013).
70. Hashizume, R. et al. Pharmacologic inhibition of histone demethylation as a therapy for pediatric brainstem glioma. Nat. Med. 20, 1394-1396 (2014).
71. Grasso, C. S. et al. Functionally defined therapeutic targets in diffuse intrinsic pontine glioma. Nat. Med. 21, 555-559 (2015).
72. Castel, D. et al. Histone H3F3A and HIST1H3B K27M mutations define two subgroups of diffuse intrinsic pontine gliomas with different prognosis and phenotypes. Acta Neuropathol. 130, 815-827 (2015).
73. Mack, S. C. et al. Epigenomic alterations define lethal CIMP-positive ependymomas of infancy. Nature 506, 445-450 (2014).
74. Weller, M. et al. EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma. Lancet Oncol. 15, e395-403 (2014).
75. Wick, W. et al. Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. Lancet Oncol. 13, 707-715 (2012).
76. Malmstrøm, A. et al. Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. Lancet Oncol. 13, 916-926 (2012).
77. van den Bent, M. J. et al. Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumour group study 26951. J. Clin. Oncol. 31, 344-350 (2013).
78. Cairncross, G. et al. Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. J. Clin. Oncol. 31, 337-343 (2013).
79. Stupp, R. et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 352, 987-996 (2005).
80. Wick, W. et al. MGMT testing - the challenges for biomarker-based glioma treatment. Nat. Rev. Neurol. 10, 372-385 (2014).
81. Hegi, M. E. et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N. Engl. J. Med. 352, 997-1003 (2005).
82. Wick, W. et al. Prognostic or predictive value of MGMT promoter methylation in gliomas depends on IDH1 mutation. Neurology 81, 1515-1522 (2013).
83. Grasbon-Frodl, E. et al. Intratumoural homogeneity of MGMT promoter hypermethylation as demonstrated in serial stereotactic specimens from anaplastic astrocytomas and glioblastomas. Int. J. Cancer 121, 2458-2464 (2007).
84. Felsberg, J. et al. Promoter methylation and expression of MGMT and the DNA mismatch repair genes MLH1, MSH2, MSH6 and PMS2 in paired primary and recurrent glioblastomas. Int. J. Cancer 129, 659-670 (2011).
85. Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455, 1061-1068 (2008).
86. Vogazianou, A. P. et al. Distinct patterns of 1p and 19q alterations identify subtypes of human gliomas that have different prognoses. Neuro Oncol. 12, 664-678 (2010).
87. Preusser, M., Bienkowski, M. & Birner, P. BRAF inhibitors in BRAF-V600 mutated primary neuroepithelial brain tumours. Expert Opin. Investig. Drugs 25, 7-14 (2016).
88. Rohle, D. et al. An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells. Science 340, 626-630 (2013).
89. Schumacher, T. et al. A vaccine targeting mutant IDH1 induces antitumour immunity. Nature 512, 324-327 (2014).
90. Sampson, J. H. et al. Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. J. Clin. Oncol. 28, 4722-4729 (2010).
91. Schuster, J. et al. A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study. Neuro Oncol. 17, 854-861 (2015).
92. Phillips, A. C. et al. ABT-414, an antibody-drug conjugate targeting a tumor-selective EGFR epitope. Mol. Cancer Ther. 15, 661-669 (2016).
93. Zahonero, C. et al. Preclinical test of dacomitinib, an irreversible EGFR inhibitor, confirms its effectiveness for glioblastoma. Mol. Cancer Ther. 14, 1548-1558 (2015).
94. Reardon, D. A. et al. ReACT: overall survival from a randomised phase II study of rindopepimut (CDX-110) plus bevacizumab in relapsed glioblastoma. J. Clin. Oncol. 33 (Suppl.), abstr 2009 (2015).
95. Singh, D. et al. Transforming fusions of FGFR and TACC genes in human glioblastoma. Science 337, 1231-1235 (2012).
96. Di Stefano, A. L. et al. Detection, characterization, and inhibition of FGFR-TACC fusions in IDH wild-type glioma. Clin. Cancer Res. 21, 3307-3317 (2015).
97. Worst, B. C. et al. Next-generation personalised medicine for high-risk paediatric cancer patients - the INFORM pilot study. Eur. J. Cancer 65, 91-101 (2016).
98. 2). J. Clin. Oncol. 34, TPS2084 (2016).
99. US National Institutes of Health. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02465060 (2016).
100. Dubbink, H. J. et al. Molecular classification of anaplastic oligodendroglioma using next-generation sequencing: a report of the prospective randomised EORTC Brain Tumour Group 26951 phase III trial. Neuro Oncol. 18, 388-400 (2016).
101. Nikiforova, M. N. et al. Targeted next-generation sequencing panel (GlioSeq) provides comprehensive genetic profiling of central nervous system tumours. Neuro Oncol. 18, 379-387 (2016).
102. Sahm, F. et al. Next-generation sequencing in routine brain tumour diagnostics enables an integrated diagnosis and identifies actionable targets. Acta Neuropathol. 131, 903-910 (2016).
103. Zacher, A. et al. Molecular diagnostics of gliomas using next generation sequencing of a glioma-tailored gene panel. Brain Pathol. http://dx.doi.org/10.1111/bpa.12367 (2016).
104. Bady, P., Delorenzi, M. & Hegi, M. E. Sensitivity analysis of the MGMT-STP27 model and impact of genetic and epigenetic context to predict the MGMT methylation status in gliomas and other tumours. J. Mol. Diagn. 18, 350-361 (2016).
105. Bettegowda, C. et al. Detection of circulating tumour DNA in early- and late-stage human malignancies. Sci. Transl. Med. 6, 224ra24 (2014).
106. De Mattos-Arruda, L. et al. Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma. Nat. Commun. 6, 8839 (2015).
107. Wang, Y. et al. Detection of tumour-derived DNA in cerebrospinal fluid of patients with primary tumours of the brain and spinal cord. Proc. Natl Acad. Sci. USA 112, 9704-9709 (2015).
108. Drusco, A. et al. A differentially expressed set of microRNAs in cerebro-spinal fluid (CSF) can diagnose CNS malignancies. Oncotarget 6, 20829-20839 (2015).
109. Shi, R. et al. Exosomal levels of miRNA-21 from cerebrospinal fluids associated with poor prognosis and tumor recurrence of glioma patients. Oncotarget 6, 26971-26981 (2015).
110. Rudà, R., Gilbert, M. & Soffietti, R. Ependymomas of the adult: molecular biology and treatment. Curr. Opin. Neurol. 21, 754-761 (2008).
111. Stummer, W. et al. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. Lancet Oncol. 7, 392-401 (2006).
112. Senft, C. et al. Intraoperative MRI guidance and extent of resection in glioma surgery: a randomised, controlled trial. Lancet Oncol. 12, 997-1003 (2011).
113. Vuorinen, V., Hinkka, S., Farkkila, M. & Jaaskelainen, J. Debulking or biopsy of malignant glioma in elderly people - a randomised study. Acta Neurochir. (Wien) 145, 5-10 (2003).
114. van den Bent, M. J. et al. Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial. Lancet 366, 985-990 (2005).
115. Daniels, T. B. et al. Validation of EORTC prognostic factors for adults with low-grade glioma: a report using intergroup 86-72-51. Int. J. Radiat. Oncol. Biol. Phys. 81, 218-224 (2011).
116. Pignatti, F. et al. Prognostic factors for survival in adult patients with cerebral low-grade glioma. J. Clin. Oncol. 20, 2076-2084 (2002).
117. Buckner, J. C. et al. Radiation plus procarbazine, CCNU, and vincristine in low-grade glioma. N. Engl. J. Med. 374, 1344-1355 (2016).
118. Baumert, B. G. et al. Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study. Lancet Oncol. 17, 1521-1532 (2016).
119. US National Institutes of Health. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT00887146 (2016).
120. Cairncross, J. G. et al. Benefit from procarbazine, lomustine, and vincristine in oligodendroglial tumors is associated with mutation of IDH. J. Clin. Oncol. 32, 783-790 (2014).
121. van den Bent, M. J. et al. MGMT-STP27 methylation status as predictive marker for response to PCV in anaplastic oligodendrogliomas and oligoastrocytomas. A report from EORTC study 26951. Clin. Cancer Res. 19, 5513-5522 (2013).
122. van den Bent, M. J. et al. Results of the interim analysis of the EORTC randomized phase III CATNON trial on concurrent and adjuvant temozolomide in anaplastic glioma without 1p/19q co-deletion, an intergroup trial [abstract]. J. Clin. Oncol. 34, LBA2000 (2016).
123. Laperriere, N. et al. Optimal management of elderly patients with glioblastoma. Cancer Treat. Rev. 39, 350-357 (2013).
124. Roa, W. et al. Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: a prospective randomised clinical trial. J. Clin. Oncol. 22, 1583-1588 (2004).
125. Perry, J. R. et al. A phase III randomised controlled trial of short-course radiotherapy with or without concomitant and adjuvant temozolomide in elderly patients with glioblastoma (CCTG CE.6, EORTC 26062-22061, TROG 08.02, NCT00482677). J. Clin. Oncol. 34, LBA2 (2016).
126. Suchorska, B. et al. Complete resection of contrast-enhancing tumour volume is associated with improved survival in recurrent glioblastoma-results from the DIRECTOR trial. Neuro Oncol. 18, 549-556 (2016).
127. Mayer, R. & Sminia, P. Reirradiation tolerance of the human brain. Int. J. Radiat. Oncol. Biol. Phys. 70, 1350-1360 (2008).
128. Batchelor, T. T. et al. Phase III randomised trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma. J. Clin. Oncol. 31, 3212-3218 (2013).
129. Wick, W. et al. Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma. J. Clin. Oncol. 28, 1168-1174 (2010).
130. Perry, J. R. et al. Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study. J. Clin. Oncol. 28, 2051-2057 (2010).
131. Weller, M. et al. MGMT promoter methylation is a strong prognostic biomarker for benefit from dose-intensified temozolomide rechallenge in progressive glioblastoma: the DIRECTOR trial. Clin. Cancer Res. 21, 2057-2064 (2015).
132. Friedman, H. S. et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J. Clin. Oncol. 27, 4733-4740 (2009).
133. Kreisl, T. N. et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumour progression in recurrent glioblastoma. J. Clin. Oncol. 27, 740-745 (2009).
134. Wick, W. et al. Phase III trial exploring the combination of bevacizumab and lomustine in patients with first recurrence of a glioblastoma: the EORTC 26101 trial [abstract LB-05]. Neuro Oncol. 17 (Suppl. 5), v1 (2015).
135. Stupp, R. et al. Maintenance therapy with tumour-treating fields plus temozolomide versus temozolomide alone for glioblastoma: a randomised clinical trial. JAMA 314, 2535-2543 (2015).
136. Wick, W. TTFields: where does all the skepticism come from? Neuro Oncol. 18, 303-305 (2016).
137. Johnson, B. E. et al. Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma. Science 343, 189-193 (2014).
138. Singh, S. K. et al. Identification of human brain tumour initiating cells. Nature 432, 396-401 (2004).
139. Bao, S. et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 444, 756-760 (2006).
140. Chen, J. et al. A restricted cell population propagates glioblastoma growth after chemotherapy. Nature 488, 522-526 (2012).
141. Lathia, J. D., Mack, S. C., Mulkearns-Hubert, E. E., Valentim, C. L. & Rich, J. N. Cancer stem cells in glioblastoma. Genes Dev. 29, 1203-1217 (2015).
142. Gallo, M. et al. MLL5 orchestrates a cancer self-renewal state by repressing the histone variant H3.3 and globally reorganizing chromatin. Cancer Cell 28, 715-729 (2015).
143. Pietras, A. et al. Osteopontin-CD44 signaling in the glioma perivascular niche enhances cancer stem cell phenotypes and promotes aggressive tumour growth. Cell Stem Cell 14, 357-369 (2014).
144. Zhu, Z. et al. Targeting self-renewal in high-grade brain tumours leads to loss of brain tumour stem cells and prolonged survival. Cell Stem Cell 15, 185-198 (2014).
145. Xu, R. et al. Molecular and clinical effects of Notch inhibition in glioma patients: a phase 0/I trial. Clin. Cancer Res. 22, 4786-4796 (2016).
146. Sloan, A. E. et al. Targeting glioma-initiating cells in GBM: ABTC-0904, a randomized phase 0/II study targeting the Sonic Hedgehog-signaling pathway. J. Clin. Oncol. 32, (2014).
147. van Thuijl, H. F. et al. Evolution of DNA repair defects during malignant progression of low-grade gliomas after temozolomide treatment. Acta Neuropathol. 129, 597-607 (2015).
148. Squatrito, M. et al. Loss of ATM/Chk2/p53 pathway components accelerates tumour development and contributes to radiation resistance in gliomas. Cancer Cell 18, 619-629 (2010).
149. Halliday, J. et al. In vivo radiation response of proneural glioma characterised by protective p53 transcriptional program and proneural-mesenchymal shift. Proc. Natl Acad. Sci. USA 111, 5248-5253 (2014).
150. Osswald, M. et al. Brain tumour cells interconnect to a functional and resistant network. Nature 528, 93-98 (2015).
151. Krueger, D. A. et al. Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis. N. Engl. J. Med. 363, 1801-1811 (2010).
152. Franz, D. N. et al. Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial. Lancet 381, 125-132 (2013).
153. Chamberlain, M. C. Salvage therapy with BRAF inhibitors for recurrent pleomorphic xanthoastrocytoma: a retrospective case series. J. Neurooncol. 114, 237-240 (2013).
154. Lee, E. Q., Ruland, S., Le Boeuf, N. R., Wen, P. Y. & Santagata, S. Successful treatment of a progressive BRAF V600E-mutated anaplastic pleomorphic xanthoastrocytoma with vemurafenib monotherapy. J. Clin. Oncol. 34, e87-89 (2016).
155. US National Institutes of Health. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT01748149 (2016).
156. Kieran, M. W. et al. The first study of dabrafenib in pediatric patients with BRAF V600-mutant relapsed or refractory low-grade gliomas. Ann. Oncol. 27 (Suppl. 6), abstr LBA19-PR (2016).
157. Sievert, A. J. et al. Paradoxical activation and RAF inhibitor resistance of BRAF protein kinase fusions characterizing pediatric astrocytomas. Proc. Natl Acad. Sci. USA 110, 5957-5962 (2013).
158. Karajannis, M. A. et al. Phase II study of sorafenib in children with recurrent or progressive low-grade astrocytomas. Neuro Oncol. 16, 1408-1416 (2014).
159. US National Institutes of Health. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT01089101 (2016).
160. Robinson, G. W., Orr, B. A. & Gajjar, A. Complete clinical regression of a BRAF V600E-mutant pediatric glioblastoma multiforme after BRAF inhibitor therapy. BMC Cancer 14, 258 (2014).
161. Galanis, E. et al. Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study. J. Clin. Oncol. 23, 5294-5304 (2005).
162. Wick, W. et al. Phase II study of radiotherapy and temsirolimus versus radiochemotherapy with temozolomide in patients with newly diagnosed glioblastoma without MGMT promoter hypermethylation (EORTC 26082). Clin. Cancer Res. 22, 4797-4806 (2016).
163. Van den Bent, M. J. et al. Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034. J. Clin. Oncol. 27, 1268-1274 (2009).
164. Stupp, R. et al. Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 15, 1100-1108 (2014).
165. Hegi, M. E., Rajakannu, P. & Weller, M. Epidermal growth factor receptor: a re-emerging target in glioblastoma. Curr. Opin. Neurol. 25, 774-779 (2012).
166. Van den Bent, M. J. et al. Efficacy of a novel antibody-drug conjugate (ADC), ABT-414, as monotherapy in epidermal growth factor receptor (EGFR) amplified, recurrent glioblastoma (GBM). J. Clin. Oncol. 34, 2542 (2016).
167. US National Institutes of Health. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02073994 (2016).
168. US National Institutes of Health. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02481154 (2016).
169. US National Institutes of Health. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02381886 (2016).
170. Liu, F. et al. EGFR mutation promotes glioblastoma through epigenome and transcription factor network remodeling. Mol. Cell. 60, 307-318 (2015).
171. Vivanco, I. et al. Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors. Cancer Discov. 2, 458-471 (2012).
172. Snuderl, M. et al. Mosaic amplification of multiple receptor tyrosine kinase genes in glioblastoma. Cancer Cell 20, 810-817 (2011).
173. Prados, M. D. et al. Toward precision medicine in glioblastoma: the promise and the challenges. Neuro Oncol. 17, 1051-1063 (2015).
174. Nduom, E. K., Weller, M. & Heimberger, A. B. Immunosuppressive mechanisms in glioblastoma. Neuro Oncol. 17, vii9-vii14 (2015).
175. Engelhardt, B. et al. Vascular, glial, and lymphatic immune gateways of the central nervous system. Acta Neuropathol. 132, 317-338 (2016).
176. Reardon, D. A. et al. Immunotherapy advances for glioblastoma. Neuro Oncol. 16, 1441-1458 (2014).
177. Weller, M. et al. ACT IV: An international, double-blind, phase 3 trial of rindopepimut in newly diagnosed, EGFRvIII-expressing glioblastoma. Neuro Oncol. 18, (Suppl. 6): vi17-vi18 (2016).
178. Mitchell, D. A. et al. Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients. Nature 519, 366-369 (2015).
179. Wen, P. et al. A randomised double blind placebo-controlled phase 2 trial of dendritic cell (DC) vaccine ICT-107 following standard treatment in newly diagnosed patients with GBM. Neuro Oncol. 16, v8-v22 (2014).
180. US National Institutes of Health. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02546102 (2016).
181. US National Institutes of Health. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT00045968 (2016).
182. Preusser, M., Lim, M., Hafler, D. A., Reardon, D. A. & Sampson, J. H. Prospects of immune checkpoint modulators in the treatment of glioblastoma. Nat. Rev. Neurol. 11, 504-514 (2015).
183. Ribas, A. et al. Phase III randomised clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. J. Clin. Oncol. 31, 616-622 (2013).
184. Wolchok, J. D. et al. Nivolumab plus ipilimumab in advanced melanoma. N. Engl. J. Med. 369, 122-133 (2013).
185. Brahmer, J. et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N. Engl. J. Med. 373, 123-135 (2015).
186. Rizvi, N. A. et al. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. Lancet Oncol. 16, 257-265 (2015).
187. Reardon, D. A. et al. Glioblastoma eradication following immune checkpoint blockade in an orthotopic, immunocompetent model. Cancer Immunol. Res. 4, 124-135 (2016).
188. Bouffet, E. et al. Immune checkpoint inhibition for hypermutant glioblastoma multiforme resulting from germline biallelic mismatch repair deficiency. J. Clin. Oncol. 34, 2206-2211 (2016).
189. US National Institutes of Health. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02017717 (2016).
190. US National Institutes of Health. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02667587 (2016).
191. US National Institutes of Health. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02617589 (2016).
192. Jena, B., Dotti, G. & Cooper, L. J. Redirecting T-cell specificity by introducing a tumour-specific chimeric antigen receptor. Blood 116, 1035-1044 (2010).
193. Davila, M. L. et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci. Transl. Med. 6, 224ra25 (2014).
194. Morgan, R. A. et al. Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy. J. Immunother. 36, 133-151 (2013).
195. Sampson, J. H. et al. EGFRvIII mCAR-modified T-cell therapy cures mice with established intracerebral glioma and generates host immunity against tumor-antigen loss. Clin. Cancer Res. 20, 972-984 (2014).
196. Shiina, S. et al. CAR T cells targeting podoplanin reduce orthotopic glioblastomas in mouse brains. Cancer Immunol. Res. 4, 259-268 (2016).
197. US National Institutes of Health. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT01454596 (2016).
198. US National Institutes of Health. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT01109095 (2016).
199. Ahmed, N. et al. Human epidermal growth factor receptor 2 (HER2)-specific chimeric antigen receptor-modified T cells for the immunotherapy of HER2-positive sarcoma. J. Clin. Oncol. 33, 1688-1696 (2015).
200. Billingham, L., Malottki, K. & Steven, N. Research methods to change clinical practice for patients with rare cancers. Lancet Oncol. 17, e70-80 (2016).
201. Galanis, E. et al. Phase 2 trial design in neuro-oncology revisited: a report from the RANO group. Lancet Oncol. 13, e196-204 (2012).
202. US National Institutes of Health. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02343406 (2016).
203. US National Institutes of Health. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02573324 (2016).
204. US National Institutes of Health. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT01112527 (2016).
205. US National Institutes of Health. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT01975701 (2016).
206. Simon, R. & Roychowdhury, S. Implementing personalised cancer genomics in clinical trials. Nat. Rev. Drug Discov. 12, 358-369 (2013).